Evidence map›Paper›PMID 24240935›Full record

ArticleJAMA2013

Trends in aortic valve replacement for elderly patients in the United States, 1999-2011.

José Augusto Barreto-Filho, Yun Wang, John A Dodson, Mayur M Desai, Lissa Sugeng, Arnar Geirsson, Harlan M Krumholz

Registry-linked trialAbstract read
In one paragraph

Article in JAMA, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03084510 (REPRISE China), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03084510 nawithdrawnnot on this mapstarted 2020, after this paper: background citation

REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China

TypeinterventionalSponsorBoston Scientific CorporationRan2020 to 2020Enrolled0ConditionsStenoses, Aortic ValveArmsLotus Edge™ Valve System
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2017
    Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

José Augusto Barreto-FilhoDivision of Cardiology, Federal University of Sergipe, and the Clínica e Hospital São Lucas, Aracaju, Sergipe, Brazil10Center for Outcomes Research and Evaluation at Yale-New Haven Hospital (during the time that the work was conducted).
Yun Wang
John A Dodson
Mayur M Desai
Lissa Sugeng
Arnar Geirsson
Harlan M Krumholz
Yale University · USBrigham and Women's Hospital · USRobert Wood Johnson Foundation · USYale New Haven Hospital · US

Funding

Center for Cardiovascular Outcomes Research at Yale UniversityU01HL105270 · NHLBI · YALE UNIVERSITY · PI CURTIS, JEPTHA PELHAM, KRUMHOLZ, HARLAN MARC · 2010 to 2013
$5.8M
NHLBI NIH HHS U01 HL105270NHLBI NIH HHS U01HL105270-04
6 · The paper itself

Abstract

importanceThere is a need to describe contemporary outcomes of surgical aortic valve replacement (AVR) as the population ages and transcatheter options emerge.

objectiveTo assess procedure rates and outcomes of surgical AVR over time. DESIGN, SETTING, AND

participantsA serial cross-sectional cohort study of 82,755,924 Medicare fee-for-service beneficiaries undergoing AVR in the United States between 1999 and 2011. MAIN OUTCOMES AND MEASURES: Procedure rates for surgical AVR alone and with coronary artery bypass graft (CABG) surgery, 30-day and 1-year mortality, and 30-day readmission rates.

resultsThe AVR procedure rate increased by 19 (95% CI, 19-20) procedures per 100,000 person-years over the 12-year period (P<.001), with an age-, sex-, and race-adjusted rate increase of 1.6% (95% CI, 1.0%-1.8%) per year. Mortality decreased at 30 days (absolute decrease, 3.4%; 95% CI, 3.0%-3.8%; adjusted annual decrease, 4.1%; 95% CI, 3.7%- 4.4%) per year and at 1 year (absolute decrease, 2.6%; 95% CI, 2.1%-3.2%; adjusted annual decrease, 2.5%; 95% CI, 2.3%-2.8%). Thirty-day all-cause readmission also decreased by 1.1% (95% CI, 0.9%-1.3%) per year. Aortic valve replacement with CABG surgery decreased, women and black patients had lower procedure and higher mortality rates, and mechanical prosethetic implants decreased, but 23.9% of patients 85 years and older continued to receive a mechanical prosthesis in 2011. CONCLUSIONS AND RELEVANCE: Between 1999 and 2011, the rate of surgical AVR for elderly patients in the United States increased and outcomes improved substantially. Medicare data preclude the identification of the causes of the findings and the trends in procedure rates and outcomes cannot be causally linked. Nevertheless, the findings may be a useful benchmark for outcomes with surgical AVR for older patients eligible for surgery considering newer transcatheter treatments.

Indexed as

AgedAged, 80 and overAge FactorsAortic ValveBicuspid Aortic Valve DiseaseBlack or African AmericanBlack PeopleCohort StudiesCoronary Artery BypassCross-Sectional StudiesFee-for-Service PlansFemaleHeart Defects, CongenitalHeart Valve DiseasesHeart Valve ProsthesisHeart Valve Prosthesis Implantation

Identifiers

PMID24240935
PMCPMC4089974
OpenAlexW2053564483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.